Medicare's GLP-1 Discount Excludes Patients with Conditions the Drugs Treat

Medicare's temporary weight loss drug discount program excludes patients with medical conditions approved for GLP-1 medications, limiting access for millions.

Medicare's 18-month GLP-1 Bridge pilot program excludes patients with FDA-approved conditions for GLP-1 medications—such as Type 2 diabetes or obstructive sleep apnea—despite covering three weight loss drugs: Wegovy, Zepbound, and Foundayo. As of August 2026, an estimated 5.9 million Medicare enrollees are excluded due to qualifying medical conditions. Eligibility requires a BMI of 35+ (or 27-34 with specific health conditions) and Medicare Part D enrollment. KFF Health News estimates 3.8 million beneficiaries qualify; if 25% enroll for the full 18 months, Medicare costs could reach $3.3 billion. This exclusion creates a critical friction point: patients like Jeff La Marca (68, New Jersey), who has severe obstructive sleep apnea and a history of heart bypass surgery, are denied access even though they meet the program's medical criteria. The program, launched in July 2026, addresses a key barrier to affordable weight loss therapy but inadvertently gates access for those with conditions the drugs treat. This friction impacts both individual health security and the commons—by restricting therapy for patients who could benefit most from the program's cost savings. Next steps include whether the program will expand eligibility beyond FDA-approved conditions or extend beyond its 18-month pilot. Caveats: Exclusions apply only to patients with conditions the drugs treat; KFF projections assume no additional patient coverage; the program is temporary and federal law previously barred Medicare from covering weight loss drugs. Source: KFF Health News (August 25, 2026).

Source: KFF Health News